Keeping Cost Out of the Drug Approval Debate

Video Library - Pricing
Andrew Stainthorpe, PhD
Andrew Stainthorpe, PhD, PASLU, NICE, talks about why the FDA should not take drug cost into account when weighing the approval of expensive medications.
Related Items
Benefits of the Single Payer Perspective
Andrew Stainthorpe, PhD
Video Library published on March 24, 2015 in Payer-Provider
Bringing the Patient into the Conversation
Andrew Stainthorpe, PhD
Video Library published on March 24, 2015 in Personalized Medicine
Using Research to Guide Quality and Quantity of Care
Andrew Stainthorpe, PhD
Video Library published on March 24, 2015 in Personalized Medicine
AMCP Weighs in on Cost-Effectiveness
C. Daniel Mullins, PhD
Video Library published on March 24, 2015 in Pricing
Quality versus Cost
C. Daniel Mullins, PhD
Video Library published on March 24, 2015 in Pricing
Last modified: March 24, 2015
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME